Viewing data from:

KARIVA

ANDA

DESOGESTREL; ETHINYL ESTRADIOL | A075863 | BARR LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: CYCLESSA(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Kariva (2023)

Total Spending

$52K

Total Claims

1,104

Beneficiaries

296

Avg Cost/Unit

$0.70

Spending Trend

$132K(2019)→$124K(2020)→$83K(2021)→$63K(2022)→$52K(2023)

YoY Change:-8.7%

5yr CAGR:-10.6%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Apr 15, 2003	ORIG -1	View Letter (PDF)
Apr 10, 2003	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.15MG,N/A;0.02MG,0.01MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Apr 5, 2002

No patent or exclusivity listings for this strength.